Orbital Therapeutics Raises $270M in Series A Financing

Orbital Therapeutics

Orbital Therapeutics, a Cambridge, MA-based company focused on developing RNA-based medicines to treat human diseases, raised $270M in Series A funding.

The round was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, and Heritage Medical Systems.

The company intends to use the funds to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement.

Led by CEO Giuseppe Ciaramella, Ph.D., Orbital Therapeutics works to enhance health with RNA-based medicines (excluding small interfering RNA) to treat human disease. The company is building a platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement.

In addition to the financing, Orbital announced the expansion of its leadership team with the appointments of Niru Subramanian as chief operating officer and Jonathan Piazza as chief financial officer, who join Gilles Besin, Ph.D., chief scientific officer, and Dr. Ciaramella on the company’s executive leadership team.

FinSMEs

26/04/2023